症状性腰椎狭窄或滑脱患者最终需手术前最大非手术治疗长期费用:5年费用分析
这项回顾性队列研究查询大型保险数据库,纳入2007至2016年接受腰椎减压融合术的症状性腰椎狭窄或滑脱患者,分析术前最大非手术治疗(MNT)的使用与费用。共4133例患者接受1至3节段后路腰椎内固定融合,MNT总直接费用为9,000,968美元,腰椎硬膜外类固醇注射(LESI)占45.5%,为最大部分;按使用治疗的患者平均每人花费4010美元。作者假设最大非手术治疗后疼痛与功能残疾改善极小,MNT的增量成本效果比(ICER)可能高度不利。
要点
- 84.4%患者使用阿片类药物,66.7%使用非甾体抗炎药(NSAIDs),65.5%接受LESI。
- MNT总直接费用9,000,968美元,LESI占4,094,646美元(45.5%),NSAIDs占1,624,217美元(18.0%),阿片类占1,279,219美元(14.2%)。
- 按使用治疗的患者平均每人术前非手术治疗花费4010美元。
核心结论
- 假设最大非手术治疗后疼痛与功能残疾改善极小,MNT的增量成本效果比(ICER)可能高度不利。
主要发现
- 497,822例合格患者中4133例(0.8%)接受1、2或3节段后路腰椎内固定融合。
- 患者中20.8%为吸烟者,44.5%患2型糖尿病,38.2%肥胖(体重指数[BMI] >30 kg/m)。
- MNT使用率:66.7%使用NSAIDs,84.4%使用阿片类药物,58.6%使用肌肉松弛剂,65.5%接受LESI,66.6%参加(原文此处未写明具体治疗),21.1%到急诊科就诊,24.9%接受脊椎按摩治疗。
- MNT总直接费用9,000,968美元;LESI占总费用最大部分(4,094,646美元,45.5%),其次为NSAIDs(1,624,217美元,18.0%)和阿片类药物费用(1,279,219美元,14.2%)。
- 按使用治疗的患者归一化,初次腰椎手术前非手术治疗平均每人花费4010美元。
关键数值与推荐
- 证据等级:3。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Retrospective cohort study. OBJECTIVE: The purpose of this study is to characterize the utilization and costs of MNTs prior to spinal fusion surgery in patients with symptomatic lumbar stenosis or spondylolisthesis. SUMMARY OF BACKGROUND DATA: The costs and utilization of long-term maximal nonoperative therapy (MNT) can be substantial, and in the current era of bundled payments, the duration of conservative therapy trials should be reassessed. METHODS: A large insurance database was queried for patients with symptomatic lumbar stenosis or spondylolisthesis undergoing index lumbar decompression and fusion procedures between 2007 and 2016. This database consists of 20.9 million covered lives and includes private/commercially insured and Medicare Advantage beneficiaries. Only patients with lumbar stenosis or spondylolisthesis and those continuously active within the insurance system for at least 5 years prior to the index operation were eligible. RESULTS: A total of 4133 out of 497,822 (0.8%) eligible patients underwent 1, 2, or 3-level posterior lumbar instrumented fusion. 20.8% of patients were smokers, 44.5% had type II DM, and 38.2% were obese (body mass index [BMI] >30 kg/m). Patient MNT utilization was as follows: 66.7% used nonsteroidal anti-inflammatory drugs (NSAIDs), 84.4% used opioids, 58.6% used muscle relaxants, 65.5% received lumbar epidural steroid injections (LESI), 66.6% attended 21.1% presented to the emergency department (ED), and 24.9% received chiropractor treatments. The total direct cost associated with all MNT prior to index spinal fusion was $9,000,968; LESI comprised the largest portion of the total cost of MNT ($4,094,646, 45.5%), followed by NSAIDS ($1,624,217, 18.0%) and opioid costs ($1,279,219, 14.2%). At the patient level, when normalized per patient utilizing therapy, an average $4010 was spent on nonoperative treatments prior to index lumbar surgery. CONCLUSION: Assuming minimal improvement in pain and functional disability after maximum nonoperative therapies, the incremental cost-effectiveness ratio (ICER) for MNTs could be highly unfavorable. LEVEL OF EVIDENCE: 3.
引用
- Adogwa O, Davison MA, Vuong VD, et al. Long-Term Costs of Maximum Nonoperative Treatments in Patients With Symptomatic Lumbar Stenosis or Spondylolisthesis that Ultimately Required Surgery: A 5-Year Cost Analysis. Spine (Phila Pa 1976). 2019. PMID: 30130337. doi:10.1097/BRS.0000000000002849
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。